A genetic test may one day predict a child’s risk of obesity in adulthood, paving the way for early interventions.

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

Trump’s budget proposal, from May, seeks to slash the Department of Health and Human Services’ budget by $31.3 billion ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Fangzhou has signed a MoU with Novo Nordisk to collaborate on the management of serious chronic diseases, including obesity and diabetes.

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

A plan to acquire and operate what is expected to become the world’s most powerful commercial quantum computer has been ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of ...

The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...